Anemia and thrombocytopenia in people living with HIV/AIDS: a narrative literature review

Amanda Marchionatti and Mariana Migliorini Parisi

Centre for Health and Rural Sciences, University of Cruz Alta, RS, Brazil

*Corresponding author: Tel.: +55 (55) 3321-1500; E-mail: mariana_parisi@yahoo.com.br

Received 5 February 2020; revised 29 March 2020; editorial decision 5 June 2020; accepted 12 June 2020

Hematologic changes are frequent complications in people living with HIV/AIDS (PLWHA). Anemia and thrombocytopenia are the most frequent multifactorial hematologic abnormalities and are associated with a low quality of life and high death rates. This study aims to describe the prevalence of anemia and thrombocytopenia in PLWHA and to identify the main clinical characteristics that aggravate these conditions in studies published in the last 10 y. A comprehensive search was performed on the PUBMED database, using the terms ‘HIV infection and anemia’ and ‘HIV infection and thrombocytopenia’. Additional searches were made in the reference lists of articles covering the theme. The selected studies reported an overall prevalence of anemia from 7.2% to 84% and of thrombocytopenia from 4.5% to 26.2%. The prevalence of thrombocytopenia and anemia were aggravated by a CD4+ T lymphocyte count of <200 cells/μL, increased viral load and coinfections or opportunistic infections. Antiretroviral therapy (ART) shows a beneficial effect, reducing the frequencies of thrombocytopenia and anemia, except in a zidovudine-based ART regimen, which worsens the anemic condition. Because anemia and thrombocytopenia are treatable comorbidities associated with increased mortality among PLWHA, physicians should monitor these risk factors in order to establish better interventions and reduce morbidity and mortality in PLWHA.

Keywords: AIDS, anemia, erythrocytes, HIV, platelets, thrombocytopenia.

Introduction

HIV is a retrovirus that causes a multi-systemic disease because of viral action on cells that express CD4 protein in their cytoplasmic membrane. The progressive immunodeficiency caused by the decrease of CD4+ T lymphocytes during HIV infection is responsible for the installation of AIDS, leading the individual to a predisposition to opportunistic infections and a lower quality of life. 1 Approximately 38 million individuals suffer from HIV worldwide, with 70% of those infected living in sub-Saharan Africa. AIDS is one of the main causes of premature death in the world.2

Hematological changes are one of the most common complications among people living with HIV/AIDS (PLWHA).3 The bone marrow, the site of blood formation, is the target of the combined effect of the HIV viral infection, the drugs used during the AIDS treatment, the inflammatory mediators released during infection and the effects of likely opportunistic pathogens. The direct and indirect effects of HIV infection on hematopoietic progenitor cells impair bone marrow homeostasis, affecting cell proliferation and differentiation during hematopoiesis. The main consequences are altered cellularity with reduction of all hematological lineages, dysplastic changes in the erythroid and granulocytic series, megaloblastic abnormalities in the erythroid series and reticulum endothelial iron block. In addition, hematopoietic progenitor cells express CD4 receptors, type 4 C-X-C chemokine receptors and type 5 chemokine receptors, making them susceptible to being infected by HIV.4,5

The effects of HIV on bone marrow mainly cause anemia and thrombocytopenia in peripheral blood, clinical conditions related to the increased risk of death in PLWHA.6 Therefore, it is essential to monitor the evolution of the blood count during HIV infection, in order to detect the development of these hematological disorders and perform the necessary clinical interventions to avoid comorbidities.7

In recent years, studies conducted in different locations around the world have shown highly different results regarding changes in erythrocytes and platelets in PLWHA.3,8-10 In addition, there are inconsistencies about the way in which the patient’s clinical characteristics may aggravate or attenuate hematological manifestations, causing great heterogeneity between studies.6,7 The introduction of antiretroviral therapy (ART) also seems to have a dichotomous effect on the hematological compartment, which, in some cases, may in fact exacerbate anemia.11 Given the diversity of results, it becomes essential for
the data available in the literature to be reviewed to demonstrate the complex effects of HIV on the hematopoietic system.

In this study, we established two questions in order to raise qualitative data that enable a comprehensive assessment of the problem of planning interventions that mitigate the effects of hematological changes in the progression of AIDS: (1) What is the prevalence of anemia in PLWHA in different locations worldwide and in different clinical conditions? and (2) What is the prevalence of thrombocytopenia in PLWHA in different locations worldwide and in different clinical conditions? Therefore, the objective of this study was to describe the prevalence of anemia and thrombocytopenia in PLWHA and to identify the main clinical characteristics that aggravate these conditions in studies published in the last 10 y.

Methods

A narrative review of literature was performed on the PUBMED database from January to March 2020. The searches used the terms ‘HIV and anemia’ and ‘HIV and thrombocytopenia’ and the filter ‘10 year’.

First, articles that had both search terms ‘HIV and anemia’ and ‘HIV and thrombocytopenia’ in the title, published in the last 10 y, were preselected. Both authors read the abstracts of these preselected articles independently. Studies that reported the prevalence and/or hematological characteristics of anemia and/or thrombocytopenia, when these criteria were identified by both researchers individually, were finally included. Literature review articles, case studies, letters to the editor and studies that did not contemplate the scope were excluded. Finally, additional searches were made in the reference lists of articles covering the theme (Figure 1).

Results and Discussion

We found 1830 articles from the crossing of the terms used in the search. First, we excluded 1250 articles because they were missing the terms ‘HIV and anemia’ and ‘HIV and thrombocytopenia’ in the title. Subsequently, we excluded 556 articles missing the prevalence of anemia and/or thrombocytopenia or that were either a literature review, letter to the editor or a case report, by reading the abstract. Therefore, we obtained 24 articles, to which 10 articles found in the reference lists of articles covering the topic were added. Finally, for this review we used 34 articles, 18 covering anemia prevalence, 7 covering thrombocytopenia prevalence and 9 covering both anemia and thrombocytopenia prevalence (Figure 1).

Anemia in people living with HIV/AIDS

Our research generated 27 articles reporting the prevalence and/or hematological features of anemia in adult PLWHA in...
the last 10 y (Table 1): 6 cohort, 18 cross-sectional, 1 longitudinal, 1 case-control and 1 randomized clinical trial. These studies reported an overall prevalence of anemia from 6.3% to 84% in PLWHA worldwide and demonstrated they have significantly lower hemoglobin levels than healthy controls in peripheral blood.12

**Anemia in people living with HIV/AIDS in different locations worldwide**

Results show that different countries have different prevalence levels of anemia in PLWHA. In this context, developed countries have a lower rate of this comorbidity during HIV infection. In a recent cohort study of PLWHA receiving care at eight sites across the USA, 7.2% of individuals developed anemia after 6 y of follow-up, indicating an incidence of anemia of 1.95/100 person-years.12 In Denmark, a longitudinal study detected the prevalence of 6.9% of anemia; however, PLWHA evaluated had an undetectable viral load, which may have contributed to the low rate of anemia observed.15

On the other hand, developing Asian countries showed higher rates of anemia in PLWHA. In Indonesia,13 the prevalence of anemia was 38.8% whereas in India16 it was 84% in the cases studied. A recent Chinese study14 showed anemia prevalence of 44.3%, 34.7% and 27.6% in 2010, 2012 and 2014, respectively, thus showing an important decline in incidence over time. All cohort studies conducted in Asia were cross-sectional, having a lower level of evidence than the longitudinal studies conducted in developed countries.

On the African continent, eight studies were conducted in Ethiopia, of which six were cross-sectional. In these cross-sectional studies,16-18,26,27,33 prevalence ranged from 20.7% to 51.5% in sample populations that contemplated PLWHA on ART and those who were ART-naïve. The two retrospective cohort studies20,25 showed a prevalence of anemia at baseline of ART of 20.8%, 44.2% and 42.9%, which declined after starting treatment. Surprisingly, striking differences were found in other African countries in cross-sectional studies. In Uganda,19 the prevalence of anemia in PLWHA who were ART-naïve was only 6.3%, while in South Africa26 it was 59.5% and, in Nigeria, 57.5%. In PWLHA on ART, the prevalence was 40.46% in Tanzania23 and 24.3% in Nigeria.35

Corroborating these data, a randomized clinical trial of ART efficacy in Africa, Asia, South America, Caribbean and the USA1 showed that anemia prevalence varied significantly among these places. In this context, prevalence of anemia was highest in Malawi, Haiti, South Africa and Zimbabwe. This study provides strong evidence that the prevalence of anemia is higher in developing countries because data were collected from PLWHA with advanced untreated HIV-1 infection living in nine countries geographically distant at the time of the patient’s entry into the clinical trial. In addition, to enter clinical trials, it is necessary to pass strict inclusion and exclusion criteria, which confers greater homogeneity in the PLWHA sample population in these studies than in independent cohorts. The differences in anemia rates between developed and developing countries can be explained by the differences in the levels of poverty, malnutrition and the overall poor economic state, which are accentuated mainly in African countries.3

**Anemia in people living with HIV/AIDS in different clinical conditions**

Disease progression and ART may influence the presence of anemia during HIV infection. To explain this, one study discussed CD4+ T lymphocyte count as a possible predictor of anemia development in PLWHA.26

Different cross-sectional studies have shown that the highest prevalence of anemia occurs in PLWHA with a CD4+ T lymphocyte count of <200 cells/µL17,19,22 characterized by peripheral immunosuppression and hematopoietic activity decline in bone marrow. A retrospective cohort study showed that a lower CD4+ T lymphocyte count was associated with anemia and severe anemia and that women with a CD4+ T lymphocyte count of <100 cells/µL were at an increased risk of developing anemia.12

Also, blood hemoglobin levels, mean corpuscular volume and mean corpuscular hemoglobin were shown to be lower in PLWHA with a CD4+ T lymphocyte count of <200 cells/µL than in PLWHA with asymptomatic HIV infection.9

Hemoglobin levels can also be useful in monitoring the PLWHA response to ART. A prospective cross-sectional study indicated that 0–6 mo after the start of ART, the increase in hemoglobin was significantly associated with an increase in CD4+ T lymphocyte count. After 6 mo of treatment, hemoglobin levels showed a sustained overall increase, regardless of the baseline CD4+ T lymphocyte count.29

In addition to CD4+ T lymphocyte count, viral load is a marker that predisposes to the development of anemia. The prevalence of anemia is higher in PLWHA with an HIV viral load upper than 400 or 1000 copies of HIV RNA per mL of blood.6,12 Thus, ART, while suppressing the individual’s viral load, may indirectly improve hemoglobin levels because it improves the erythropoietic dysfunction resulting from the increased viral load. In fact, a longitudinal study15 revealed a prevalence of 6.9% of anemia in PLWHA with undetectable viral load, suggesting that patients with controlled disease have fewer hematological comorbidities.

The HIV treatment influences the development of anemia. Some authors have described the beneficial effect of ART on the frequency of anemia during HIV infection. A recent study conducted in a sample of 1061 individuals showed a prevalence of 42.9% of anemia before ART. However, after 6 mo of the therapeutic regimen, the prevalence of anemia was reduced to 20.9% and, after 1 y of the therapeutic regimen, this rate decreased to 14.3%.25 Another study in a sample of 234 PLWHA displayed an anemia prevalence of 23.1%; however, when these individuals were divided into two groups according to treatment, the prevalence of anemia in the group receiving ART was 16.2% and in the group not receiving ART it was 29.9%.25 In Nigeria, a study conducted with 500 PLWHA showed that the prevalence of anemia was lower and the mean hemoglobin concentration was significantly higher in patients receiving ART.28 In addition, there was an increase in hemoglobin levels 6 months after ART and a non-zidovudine (ZDV)-based ART regimen reduced the odds of anemia.13

Nevertheless, Takuva et al.29 found a prevalence of 25.8% of anemia in a population of 10 259 PLWHA in South Africa. After starting treatment in 322 of these individuals, the percentage of anemia was doubled. The therapeutic regimen used was based on ZDV, which is described as a possible inhibitor of erythroid
| Study design            | Sample                                                                 | Main results                                                                 | Place, year | Reference |
|------------------------|------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------|-----------|
| Retrospective          | 15 126 PLWHA                                                          | - 7.2% PLWHA developed anemia during a median follow-up of 6.6 y              | USA, 2020   | 12        |
| cohort study            |                                                                        | - 3.1% PLWHA developed severe anemia during a median follow-up of 6.6 y      |             |           |
|                        |                                                                        | - Older age, female gender, black race, HCV coinfection, lower CD4 cell counts, viral load $\geq$ 400 copies/mL were associated with incident anemia |             |           |
| Observational          | 199 PLWHA with severe anemia, 45.7% on ART                           | - 42.2% PLWHA had very severe anemia (hemoglobin $\leq$ 50 g/L).             | Malawi, 2020| 6         |
| cohort study            |                                                                        | - 96% of the patients had more than two potential causes for anemia: iron deficiency (55.3%), underweight (73.9%), TB infection (41.2%), viral load $> 1000$ copies/mL (73.9%) |             |           |
|                        |                                                                        | - Overall mortality in anemic patients was 53%                               |             |           |
|                        |                                                                        | - EBV/CMV coinfection (16.5%) associated with very severe anemia             |             |           |
| Retrospective          | 440 PLWHA on ART                                                      | - Improved mean hemoglobin level 6 mo after ART in females                  | Ghana, 2020 | 13        |
| cohort study            |                                                                        | - Non-ZDV ART-based regimen reduced odds of anemia in males                 |             |           |
| Cross-sectional        | 1456 PLWHA in 2010, 1531 PLWHA in 2012 and 1567 PLWHA in 2014          | - Prevalence of anemia: 44.3%, 34.7% and 27.6% in PLWHA in 2010, 2012 and 2014, respectively | China, 2019 | 14        |
| study                  |                                                                        | - Patients with a higher level of education had a lower risk of anemia in 2014 |             |           |
|                        |                                                                        | - Patients receiving a longer duration of ART had a higher risk of anemia in 2014 |             |           |
| Longitudinal study     | 796 PLWHA with undetectable viral load (HIV RNA $< 50$ copies/mL) and 2388 uninfected controls | - Prevalence of anemia significantly higher in PLWHA (6.9%) than in uninfected controls (3.4%) | Denmark, 2019| 15        |
|                        |                                                                        | - HIV independently associated with anemia                                  |             |           |
| Cross-sectional        | 411 PLWHA, 75% on HAART                                               | - Prevalence of anemia: 36.5%                                               | Ethiopia, 2019| 16        |
| study                  |                                                                        | - PLWHA $> 5$ y, low CD4 count, infection with intestinal parasites, low BMI and being HAART-naive associated with anemia prevalence |             |           |
| Cross-sectional        | 320 PLWHA on ART, the regimen consisted of a combination of nucleoside and non-nucleoside reverse transcriptase inhibitors | - Prevalence of anemia: 25%                                                | Ethiopia, 2015| 17        |
| study                  |                                                                        | - 2.5% PLWHA had severe and 21.3% moderate anemia                          |             |           |
|                        |                                                                        | - 45% had macrocytic anemia                                                 |             |           |
|                        |                                                                        | - HAART-naive and CD4 count $< 200$ cells/$\mu$L as independent and significant anemia predictors |             |           |
| Cross-sectional        | 364 PLWHA, 133 on HAART and 231 HAART-naive                          | - Prevalence of anemia: 51.5%                                              | Ethiopia, 2018| 18        |
| study                  |                                                                        | - 32.2% had macrocytic anemia                                               |             |           |
| Study design               | Sample                                                                 | Main results                                                                 | Place, year | Reference |
|----------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------------|-------------|-----------|
| Cross-sectional study      | 141 PLWHA ART-naive                                                   | - Prevalence of anemia: 6.3%                                                 | Uganda, 2018| 19        |
|                            |                                                                       | - CD4 count < 200 cells/μL associated to anemia                              |             |           |
|                            |                                                                       | - 89.4% had normocytic anemia                                                |             |           |
| Retrospective cohort study | 197 PLWHA on ZDV-based ART and 197 non-ZDV-based ART                  | - Prevalence of anemia: 20.8%, 33.5% and 13% (baseline, 6 and 12 mo of ART follow-up among ZDV group) | Ethiopia, 2018| 20        |
|                            |                                                                       | - Prevalence of anemia: 44.2%, 18.3% and 12.4% (baseline, 6 and 12 mo of ART follow-up among non-ZDV group) |             |           |
|                            |                                                                       | - 45% had macrocytic anemia in ZDV group                                    |             |           |
|                            |                                                                       | - ZDV group 3.34-fold more likely to develop severe anemia than non-ZDV group|             |           |
| Cross-sectional study      | 54 PLWHA on ART for more than 6 wk                                    | - Prevalence of anemia: 38.8%                                                | Indonesia, 2018 | 21        |
|                            |                                                                       | - 55.1% had macrocytic anemia                                                |             |           |
|                            |                                                                       | - White blood cells < 5 × 10^9 /L and CD4 < 200 cells/μL were associated with higher rates of anemia |             |           |
| Hospital-based cross-sectional study | 377 PLWHA                                                             | - Prevalence of anemia: 23%                                                  | Ethiopia, 2017 | 33        |
|                            |                                                                       | - Being ART-naive, having treatment history with anti-TB drugs, ZDV-based ART regimen and CD4 > 200 cells/μL were associated with anemia |             |           |
| Cross-sectional study      | 307 PLWHA                                                             | - Prevalence of anemia: 59.6%                                                | South Africa, 2017 | 22        |
|                            |                                                                       | - CD4 count < 200 cells/μL associated with anemia                            |             |           |
| Cross-sectional study      | 94 PLWHA, 29 ART-naive, 31 on ZDV-based ART, 34 on non-ZDV-based ART and 20 healthy controls | - PLWHA on ZDV-based ART had mean MCV and RDW higher than control group and ART-naive group | Nigeria, 2016 | 35        |
| Cross-sectional cohort clinic-based study | 346 PLWHA on HAART                                                  | - Prevalence of moderate to severe anemia: 40.46%                           | Tanzania, 2016 | 23        |
|                            |                                                                       | - ZDV-based ART and CD4 count < 200 cells/μL as strongly predictors of anemia |             |           |
|                            |                                                                       | — MCV > 100 fl in most anemic patients                                       |             |           |
| Comparative cross-sectional study | 319 PLWHA, 219 on HAART (for at least 3 mo) and 100 HAART-naive patients | - Prevalence of anemia: 23.8%                                                | Ghana, 2016  | 24        |
|                            |                                                                       | - Higher prevalence of anemia in HAART-naive patients                       |             |           |
|                            |                                                                       | - Severe anemia related to decreased serum iron concentration               |             |           |
| Retrospective cohort study | 1061 PLWHA on HAART                                                   | - Prevalence of anemia at baseline: 42.9%                                   | Ethiopia, 2015 | 25        |
|                            |                                                                       | - Prevalence of anemia significantly decreased to 20.9% at 6 mo and to 14.3% at 12 mo after HAART initiation |             |           |
| Study design            | Sample                                                                 | Main results                                                                                                    | Place, year | Reference |
|------------------------|------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|-------------|-----------|
| Comparative cross-sectional study | 234 PLWHA, 117 on HAART and 117 HAART-naive. | - Prevalence of anemia: 23.1%  
- Prevalence of anemia in HAART-naive and HAART-experienced PLWHA was 29.9% and 16.2%, respectively  
- Presence of opportunistic infections, CD4 count <200 cells/μL and rural residence as predictors of anemia in HAART-naive PLWHA  
- HAART regimen (ZDV/3TC/NVP) and the duration of HAART as predictors of anemia for HAART-experienced groups | Ethiopia, 2014 | 26        |
| Cross-sectional study  | 290 PLWHA, 145 on ART and 145 ART-naive                               | - Prevalence of anemia: 20.7%  
- Prevalence of anemia was 11.7% in PLWHA on HAART; 29.7% in HAART-naive patients  
- 58.8% of macrocytic anemia cases on PLWHA on HAART | Ethiopia, 2014 | 27        |
| Cross-sectional study  | 500 PLWHA, 185 on HAART and 315 HAART-naive                           | - Prevalence of anemia in HAART-naive patients was 57.5%, significantly higher compared with PLWHA on HAART (24.3%)  
- The use of HAART not associated with severe anemia | Nigeria, 2013 | 28        |
| Cross-sectional study  | 1948 PLWHA newly diagnosed with HIV/AIDS                               | - Prevalence of anemia: 51.9%  
- Prevalence of mild, moderate and severe anemia was 32.4%, 17.0% and 2.5%  
- Prevalence of anemia increased with age and decreasing CD4 count | China, 2013 | 34        |
| Prospective cohort study | 10 259 PLWHA initiating first-line ART                                | - Prevalence of anemia at ART initiation: 25.8%  
- After ART initiation, hemoglobin increase linearly related to CD4 count | South Africa, 2013 | 29        |
| Cross-sectional study  | 250 PLWHA                                                              | - Prevalence of anemia: 84%  
- 40.4% had normocytic anemia  
- Prevalence of anemia in PLWHA with CD4 <200 cells/μL: 91.4% | India, 2012 | 10        |
| Cross-sectional study  | 710 PLWHA ART-naive and 226 uninfected controls                       | - Higher prevalence of anemia in PLWHA (20.5%) in relation to controls (6.3%)  
- BMI, CD4 count 200–350 cells/μL and CD4 count <200 cells/μL were associated with anemia | Rwanda, 2012 | 30        |
| Retrospective cross-sectional study | 701 PLWHA                        | - Prevalence of anemia: 37.5%  
- Prevalence of anemia in low CD4 count group: 61.1%  
- Prevalence of macrocytic anemia: 45%  
- Higher mortality rate in PLWHA with low hemoglobin concentrations | Brazil, 2011 | 31        |
| Case-control study     | 48 PLWHA on ART at least 6 mo and 45 healthy subjects as controls     | Lower hemoglobin levels in PLW-HIV than healthy controls                                                                 | Brazil, 2010 | 32        |
| Randomized clinical trial | 1532 PLWHA ART-naive                                                | - Prevalence of anemia: 12%  
- Anemia associated with gender (female), platelet count and country  
- Higher prevalence of anemia in Malawi, Haiti, South Africa and Zimbabwe | Africa, Asia, South America, Caribbean and USA, 2010 | 3          |

ART: antiretroviral therapy; BMI: body mass index; CMV: cytomegalovirus; EBV: Epstein–Barr virus; HAART: highly active ART; HCV: hepatitis C virus; MCV: mean corpuscular volume; NVP: nevirapine; RDW: red blood cell distribution width; 3TC: lamivudine; ZDV: zidovudine.
| Study Design                | Sample                                                                 | Main results                                                                                                                                                                                                 | Place, year | Reference |
|---------------------------|------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|-----------|
| Retrospective cohort study| 440 PLWHA on ART                                                      | - Reduced mean platelet count 6 mo after ART                                                                                                                                                               | Ghana, 2020 | 13        |
| Cross-sectional study     | 310 PLWHA                                                             | - Prevalence of thrombocytopenia: 19%  
- ART-naive PLWHA, viral load $>3 \log_{10}$ RNA/mL, CD4 count $<200$ cells/µL associated with higher prevalence of thrombocytopenia  | Cameroon, 2019 | 66        |
| Longitudinal study        | 796 PLWHA with undetectable viral load (HIV RNA $<50$ copies/mL) and 2388 uninfected controls | - Prevalence of thrombocytopenia was significantly higher in PLWHA (5.5%) than in uninfected controls (2.7%)  
- Thrombocytopenia independently associated with anemia  | Denmark, 2019 | 15        |
| Cross-sectional study     | 133 PLWHA on HAART and 231 PLWHA HAART-naive                         | - Prevalence of thrombocytopenia: 11.1%  
- Mean platelet count higher in PLWHA with CD4 count $>200$ cells/µL  | Ethiopia, 2018 | 18        |
| Cross-sectional study     | 320 PLWHA on ART; regimen consisted of a combination of nucleoside and non-nucleoside reverse transcriptase inhibitors | - Prevalence of thrombocytopenia: 6.3%  | Ethiopia, 2018 | 17        |
| Cross-sectional study     | 141 PLWHA ART-naive                                                  | - Prevalence of thrombocytopenia: 26.2%  
- CD4 count $<200$ cells/µL associated with thrombocytopenia  | Uganda, 2018 | 19        |
| Cross-sectional study     | 307 PLWHA                                                             | - Prevalence of thrombocytopenia: 12.1%  | South Africa, 2017 | 22        |
| Cross-sectional study     | 1948 PLWHA newly diagnosed                                           | - Prevalence of thrombocytopenia: 15.6%  
- Lower CD4 count and HIV transmitted through blood were significantly associated with an increased risk of thrombocytopenia  | China, 2015 | 47        |
| Retrospective cross-sectional study | 15 030 PLWHA                                                      | - Prevalence of thrombocytopenia: 17.4%  
- Significant association between thrombocytopenia and other cytopenias, CD4 counts, ART and deteriorating HIV stage  
- 5% of PLWHA had antiplatelet antibodies  | Uganda, 2018 | 65        |
| Cross-sectional study     | 1730 PLWHA HAART-naive                                               | - Prevalence of thrombocytopenia: 4.5%  
- Age $\geq50$ y, HCV-Ab positivity and CD4 50–199 cells/µL significantly associated with thrombocytopenia  | China, 2015 | 8         |
| Cross-sectional study     | 290 PLWHA, 145 on ART and 145 ART-naive                             | - Prevalence of thrombocytopenia: 6.6%  
- Increased prevalence of thrombocytopenia observed in PLWHA with CD4 count $<200$ cells/µL.  | Ethiopia, 2014 | 27        |
| Retrospective cross-sectional study | 390 PLWHA HAART-naive                                             | - Prevalence of thrombocytopenia: 5.9%  
- PLWHA aged $\geq50$ y were 2.5-fold more likely to have thrombocytopenia  
- PLWHA whose CD4 count $<350$ cells/µL were 2.6-fold more likely to have thrombocytopenia than PLWHA whose CD4 count $\geq500$ cells/µL  | Ethiopia, 2014 | 44        |
Table 2. continued

| Study Design                                    | Sample                          | Main results                                                                                     |
|-------------------------------------------------|---------------------------------|--------------------------------------------------------------------------------------------------|
| Cross-sectional study                           | 710 PLWHA ART-naive and 226 uninfected controls | - Higher prevalence of thrombocytopenia: 18%                                                     |
| Cross-sectional study                           | 250 PLWHA                       | - Increased prevalence of thrombocytopenia in PLWHA with CD4 count < 200 cells/μL                  |
| Retrospective cross-sectional study             | 5290 PLWHA                      | - Prevalence of severe thrombocytopenia: 0.6%                                                     |
| Retrospective cross-sectional study             | 5290 PLWHA                      | - Prevalence of thrombocytopenia: 26%                                                              |
| Retrospective cross-sectional study             | 5290 PLWHA                      | - Prevalence of thrombocytopenia: 63.6% PLWHA with immune thrombocytopenic purpura                |
| Retrospective cross-sectional study             | 5290 PLWHA                      | - Prevalence of thrombocytopenia: 18%                                                              |
| Retrospective cross-sectional study             | 5290 PLWHA                      | - Prevalence of thrombocytopenia: 18%                                                              |
| Randomized clinical trial                       | 1532 PLWHA ART-naive            | - Prevalence of thrombocytopenia: 25.4% PlWHA with platelet production deficiency                  |
| ARV: antiretroviral therapy, HAART: highly active antiretroviral therapy | 1532 PLWHA ART-naive            | - Prevalence of thrombocytopenia: 25.4% PlWHA with platelet production deficiency                  |
| Place, year                                     | Rwanda, 2012                     | - HAART improved platelets count 3 mo after starting treatment                                     |
| Place, year                                     | India, 2012                      | - Prevalence of severe thrombocytopenia: 0.6%                                                     |
| Place, year                                     | Canada, 2012                     | - Prevalence of thrombocytopenia: 26%                                                              |
| Place, year                                     | Brazil, 2012                     | - Prevalence of thrombocytopenia: 26%                                                              |
| Place, year                                     | Africa, Asia, South America, Australia and the USA, 2010 | - Prevalence of thrombocytopenia: 26%                                                              |
Thrombocytopenia in people living with HIV/AIDS in different locations worldwide

Our research shows that different countries have different prevalence levels of thrombocytopenia in PLWHA. Different to the findings above with regard to anemia, the prevalence of thrombocytopenia does not appear to be higher in developing countries than in developed countries.

An earlier cross-sectional study in Canada showed a prevalence of 26% of thrombocytopenia. A longitudinal study conducted in Denmark detected a prevalence of 5.5% of thrombocytopenia. However, PLWHA evaluated had an undetectable viral load, which may have contributed to the low rate of thrombocytopenia observed.

On the African continent, cross-sectional studies with small sample sizes conducted with PLWHA on ART and those who were ART-naïve demonstrated 11.1% and 6.6%, respectively, of thrombocytopenia in Ethiopia. However, a cross-sectional study with large sample size conducted with PLWHA on ART and those who were ART-naïve demonstrated 17.4% of thrombocytopenia in Uganda. Besides, cross-sectional studies conducted with only PLWHA who were ART-naïve demonstrated 26.2% of thrombocytopenia in Uganda, 5.9% in Ethiopia and 13.5% in Rwanda.

In Asia, a cross-sectional study conducted in India showed a prevalence of 18% of thrombocytopenia. A cross-sectional study developed in China, with a large sample of newly diagnosed PLWHA, revealed a prevalence of 15.6% of thrombocytopenia, while another study conducted in the same country with a large sample of PLWHA who were ART-naïve found a prevalence of only 4.5% of thrombocytopenia.

Corroborating these data, a randomized clinical trial of ART efficacy in Africa, Asia, South America, the Caribbean and the USA showed an overall prevalence of thrombocytopenia of 7.2%, with the highest levels of prevalence in India, Brazil, Malawi and the USA.

Thrombocytopenia in people living with HIV/AIDS in different clinical conditions

An individual’s degree of immunosuppression and use of ART can influence thrombocytopenia development. In this context, a study carried out in Uganda with 400 individuals reported a prevalence of 15.3% of thrombocytopenia in PLWHA with a CD4+ T lymphocyte count of 50–200 cells/μL, 6.6% in PLWHA with a CD4+ T lymphocyte count of 50–200 cells/μL, 9.1% in PLWHA with a CD4+ T lymphocyte count of 50–200 cells/μL and 0% in PLWHA with a CD4+ T lymphocyte count of >350 cells/μL. Corroborating these results, a study carried out in Ethiopia found similar results, with a higher prevalence of thrombocytopenia in PLWHA with a CD4+ T lymphocyte count of <200 cells/μL. By contrast, a study of 710 Rwandan women living with HIV/AIDS found no significant difference between the frequencies of thrombocytopenia when the groups were stratified according to CD4+ T lymphocyte count, suggesting a non-association of CD4+ T lymphocytes and thrombocytopenia in this population.

Moreover, the age of individuals may influence the development of thrombocytopenia during HIV infection. There is an increase in the prevalence of thrombocytopenia according to...
advancing age, which can be explained by the higher incidence of myelodysplasia in older patients.\textsuperscript{8,37}

Prior to the implementation of ART, there was a higher prevalence of thrombocytopenia in PLWHA.\textsuperscript{50} This leads to the conclusion that adherence to the therapeutic regimen influences the development of thrombocytopenia. A recent study shows that, among those PLWHA who were ART-naive, the prevalence of thrombocytopenia is 64.6%, whereas among PLWHA on ART, the prevalence of thrombocytopenia is 6.9%.\textsuperscript{46} A study carried out in Uganda showed that PLWHA on ART had a prevalence of 13% of thrombocytopenia, while in the absence of ART the prevalence was 17.8%. What is more, this study indicated the positive effect of ZDV on platelet homeostasis and lysis in the reticuloendothelial system of the spleen or early apoptosis, resulting in idiopathic thrombocytopenic purpura or immune thrombocytopenic purpura.\textsuperscript{51} A study conducted in Canada showed that 0.6% of PLWHA developed severe immune thrombocytopenic purpura, of whom 55% presented clinical bleeding and 33.3% were ART-naive.\textsuperscript{9} Similarly, 5% of PLWHA had antiplatelet antibodies in a large study developed in Uganda.\textsuperscript{45}

By contrast, the decrease in platelet production usually occurs at the onset of infection due to cross-reactivity between glycoprotein 120 in the virus envelope and platelet glycoprotein IIIa. This antibody cross-reactivity promotes platelet capture and lysis in the reticuloendothelial system of the spleen or early apoptosis, resulting in idiopathic thrombocytopenic purpura or immune thrombocytopenic purpura.\textsuperscript{51} A study conducted in Canada showed that 0.6% of PLWHA developed severe immune thrombocytopenic purpura, of whom 55% presented clinical bleeding and 33.3% were ART-naive.\textsuperscript{9} Similarly, 5% of PLWHA had antiplatelet antibodies in a large study developed in Uganda.\textsuperscript{45}

Hematological aspects and causes of thrombocytopenia in PLWHA

In line with a narrative literature review of the prevalence of thrombocytopenia in PLWHA, this section will now present a comprehensive understanding of the etiology and pathophysiology of thrombocytopenia in PLWHA.
Coinfection with hepatitis C (HCV) and B (HBV) viruses can also induce thrombocytopenia in PLWHA due to the possible presence of liver damage, responsible for reducing thrombopoietin production. A study carried out with 38 PLWHA reported that patients with a normal platelet count had serum thrombopoietin levels higher than in those who had severe thrombocytopenia. In addition, all patients with severe thrombocytopenia tested positive for antibodies against the hepatitis B virus core antigen. Furthermore, a recent study showed that the prevalence of thrombocytopenia was 10.2% in PLWHA who had HCV coinfection, higher than those found in PLWHA patients who did not have hepatitis C (3.9%).

Considering that thrombocytopenia is the first hematological manifestation of HIV infection and that it has a strong relationship with the development of AIDS, platelet count can predict the evolution from asymptomatic HIV infection to AIDS. Monitoring thrombocytopenia development is even more essential in PLWHA with HCV and HBV coinfections because they may aggravate thrombocytopenia in these patients. ART coverage appears as an independent factor in preventing the occurrence of thrombocytopenia, justifying universal treatment for all PLWHA.

**Conclusion**

HIV infection can induce several hematological manifestations, mainly anemia and thrombocytopenia (Figure 2). Because anemia and thrombocytopenia are treatable comorbidities associated with increased mortality among PLWHA, physicians should be aware of these risk factors. Hemoglobin levels and platelet count should be monitored routinely, especially among PLWHA. Hemoglobin levels and platelet count can predict the development of AIDS, platelet count can predict the evolution from asymptomatic HIV infection to AIDS. Monitoring thrombocytopenia development is even more essential in PLWHA with HCV and HBV coinfections because they may aggravate thrombocytopenia in these patients. ART coverage appears as an independent factor in preventing the occurrence of thrombocytopenia, justifying universal treatment for all PLWHA.

Authors’ contributions AM: study implementation, analysis and interpretation of data, major contribution to writing, read and approved the final version; MMP: study design, study implementation, analysis and interpretation of data, read and approved the final version.

Acknowledgements: We thank Dr. Alandra Raquel Lazzari Barlete for reviewing the manuscript for grammatical accuracy.

Funding: None.

Competing interests: None to declare.

Ethical approval: Not required.

References

1. Ghiasvand H, Waye KM, Noroozi M, Harouni GG, Armoon B, Bayani A. Clinical determinants associated with quality of life for people who live with HIV/AIDS: a meta-analysis. BMC Health Serv Res. 2019;19(1):768.

2. WHO. Report on the Global AIDS Epidemic. In: UNAIDS, editor. Switzerland; 2019.

3. Finnhaber C, Smeaton L, Saikia N., et al. Comparisons of anemia, thrombocytopenia, and neutropenia at initiation of HIV antiretroviral therapy in Africa, Asia, and the Americas. Int J Infect Dis. 2010;14(12):e1088–92.

4. Dhurve SA, Dhurve AS. Bone marrow abnormalities in HIV disease. Mediterr J Hematol Infect Dis. 2013;5(1):e2013033.

5. Tsukamoto T. Hematopoietic stem/progenitor cells and the pathogenesis of HIV/AIDS. Front Cell Infect Microbiol. 2020;10:60.

6. Huibers MHW, Bates I, Mckew S, et al. Severe anaemia complicating HIV in Malawi; multiple co-existing aetiologies are associated with high mortality. PLoS One. 2020;15(2):e0218695.

7. Fangman JJ, Scadden DT. Anemia in HIV-infected adults: epidemiology, pathogenesis, and clinical management. Curr Hematol Rep. 2005;4(2):95–102.

8. Fan HW, Guo FP, Li YJ, Li N, Li TS. Prevalence of thrombocytopenia among Chinese adult antiretroviral-naive HIV-positive patients. Chin Med J. 2015;128(4):459–64.

9. Ambler KL, Vickers LM, Leger CS, et al. Clinical features, treatment, and outcome of HIV-associated immune thrombocytopenia in the HAART era. Adv Hematol. 2012;2012:910954.

10. Parinitha S, Kulkarni M. Haematological changes in HIV infection with correlation to CD4 cell count. Australas Med J. 2012;5(3):157–62.

11. Mildvan D, Creagh T, Leitz G, Anemia Prevalence Study Group. Prevalence of anemia and correlation with biomarkers and specific antiretroviral regimens in 9690 human-immunodeficiency-virus-infected patients: findings of the Anemia Prevalence Study. Curr Med Res Opin. 2007;23(2):343–55.

12. Harding BN, Whitney BM, Nance RM, et al. Anemia risk factors among people living with HIV across the United States in the current treatment era: a clinical cohort study. BMC Infect Dis. 2020;20(1):238.

13. Obiri-Yeboah D, Charwudzi A, Baidoo IK, et al. Haematological changes among HIV-positive persons on antiretroviral therapy at a tertiary hospital in Ghana. West Afr J Med. 2020;37(1):40–7.

14. Jin Y, Meng X, Liu S, et al. Prevalence trend and risk factors for anemia among patients with human immunodeficiency virus infection receiving antiretroviral therapy in rural China. J Trad Chin Med. 2019;39(1):111–7.

15. Akdag D, Knudsen AD, Thudium RF, et al. Increased risk of anemia, neutropenia, and thrombocytopenia in people with human immunodeficiency virus and well-controlled viral replication. J Infect Dis. 2019;220(11):1834–42.

16. Ageru TA, Koyra MM, Gideon KD, Abiso TL. Anemia and its associated factors among adult people living with human immunodeficiency virus at Wolaita Sodo University teaching referral hospital. PLoS One. 2019;14(10):e0221853.

17. Deressa T, Damtie D, Workineh M, Genetu M, Melku M. Anemia and thrombocytopenia in the cohort of HIV-infected adults in northwest Ethiopia: a facility-based cross-sectional study. Eijfcc. 2018;29(1):36–47.

18. Fekene TE, Juhar LH, Mengesha CH, Worku DK. Prevalence of cytopenias in both HAART and HAART naïve HIV infected adult patients in Ethiopia: a cross sectional study. BMC Hematol. 2018;18:8.

19. Katemba C, Muzoora C, Mwanguzi E, Mwaami B, Atuhairwe C, Taremwa IM. Hematological abnormalities in HIV-antiretroviral therapy naïve clients as seen at an immune suppression syndrome clinic at Mbarara Regional Referral Hospital, southwestern Uganda. J Blood Med. 2018;9:105–10.
20 Tamir Z, Alemu J, Tsegaye A. Anemia among HIV infected individuals taking ART with and without zidovudine at Addis Ababa, Ethiopia. Ethiop J Health Sci. 2018;28(1):73–82.

21 Wahyuwibowo J, Harumansri S, Zulaikha ST, Suwondo A, Sofo MAU, Hadisaputro S. Age and CD4 count are dominant factors in the prediction of anaemia in Javanese HIV patients. Asia Pac J Clin Nutr. 2018;27(3):649–54.

22 Vaughan JL, Wiggill TM, Alli N, Hodkinson K. The prevalence of HIV seropositivity and associated cytopenias in full blood counts processed at an academic laboratory in Soweto, South Africa. S African Med J. 2017;107(3):264–9.

23 Gunda DW, Kilonzo SB, Mpondo BC. Magnitude and correlates of moderate to severe anaemia among adult HIV patients receiving first line HAART in Northwestern Tanzania: a cross sectional clinic based study. Pan African Med J. 2016;23:26.

24 Obirikorang C, Issahaku RG, Osei-Yeboah J. Anaemia and iron homeostasis in a cohort of HIV-infected patients: a cross-sectional study in Ghana. AIDS Res Treat. 2016;2016:1623094.

25 Assefa M, Abegaz WE, Shewamare A, Medhin G, Belay M. Prevalence and correlates of anaemia among HIV infected patients on highly active anti-retroviral therapy at Zewditu Memorial Hospital, Ethiopia. BMC Hematol. 2015;15:6.

26 Gedeafow L, Yemane T, Sahlemariam Z, Yilma D. Anemia and risk factors in HAART naive and HAART experienced HIV positive persons in south west Ethiopia: a comparative study. PLoS One. 2013;8(8):e72202.

27 Enawgaw B, Alem M, Addis Z, Melku M. Determination of hematological and immunological parameters among HIV positive patients taking highly active antiretroviral treatment and treatment naive in the antiretroviral therapy clinic of Gondar University Hospital, Gondar, Northwest Ethiopia: a comparative cross-sectional study. BMC Hematol. 2014;14(1):8.

28 Denue BA, Kida IM, Hammagabdo A, Dayar A, Sahabi MA. Prevalence of anemia and immunological markers in HIV-Infected patients on highly active antiretroviral therapy in Northeastern Nigeria. Infect Dis. 2013;6:25–33.

29 Takuva S, Maskew M, Brennan AT, Sanne I, Macphail AP, Fox MP. Anemia among HIV-infected patients initiating antiretroviral therapy in South Africa: Improvement in hemoglobin regardless of degree of immunosuppression and the initiating ART regimen. J Trop Med. 2013;2013:162950.

30 Munyazeso E, Emile I, Mutimura E, et al. Assessment of haematological parameters in HIV-infected and uninfected Rwandan women: a cross-sectional study. BMJ Open. 2012;2(6):e001600.

31 De Santis GC, Brunetta DM, Vilar FC, et al. Hematological abnormalities in HIV-infected patients. Int J Infect Dis. 2011;15(12):e808–11.

32 Dannehl EN, Tritinger A, Spada C. Hematological abnormalities in patients infected with human immunodeficiency virus on antiretroviral therapy with and without protease inhibitors. Rev Bras Hematol Hemoter. 2010;32(1):10–15.

33 Melese H, Wassie MM, Wolfie H, Tadesse A, Mesfin N. Anemia among adult HIV patients in Ethiopia: a hospital-based cross-sectional study. HIV/AIDS. 2017;9:25–30.

34 Shen Y, Hong Z, Lu H, et al. Prevalence of anaemia among adults with newly diagnosed HIV/AIDS in China. PLoS One. 2013;8(9):e73807.

35 Mekonnen Y, Dukers NH, Sanders E, et al. Simple markers for initiating antiretroviral therapy among HIV-infected Ethiopians. Ethiop Med J. 2003;41(Suppl 1):61–5.

36 Redig AJ, Berliner N. Pathogenesis and clinical implications of HIV-related anemia in 2013. Hematology Am Soc Hematol Educ Program. 2013;2013:377–81.

37 Vishnu P, Aboulafia DM. Haematological manifestations of human immune deficiency virus infection. Br J Haematol. 2015;171(5):695–709.

38 Paltiel O, Falutz J, Veillevius M, Rosenblatt DS, Gordon K. Clinical correlates of subnormal vitamin B12 levels in patients infected with the human immunodeficiency virus. Am J Hematol. 1995;49(4):318–22.

39 Volberding PA, Levine AM, Dieterich D, et al. Anemia in HIV infection: clinical impact and evidence-based management strategies. Clin Infect Dis. 2004;38(10):1454–63.

40 Toy PT, Reid ME, Burns M. Positive direct antiglobulin test associated with hyperglobulinemia in acquired immunodeficiency syndrome (AIDS). Am J Hematol. 1985;19(2):145–50.

41 Sanyanu AO, Fagbenro-Beyioku AF, Oyibo WA, Badarou OS, Onyeabor OS, Naameka CI. Malaria and HIV co-infection and their effect on haemoglobin levels from three health-care institutions in Lagos, southwest Nigeria. Afr Health Sci. 2013;13(2):295–300.

42 Adediran A, Osunkulu V, Wakama T, et al. Impact of HIV infection and cytopenia and thrombocytopenia on RBC parameters and urine methylmalonic acid levels. Interdisciplinary Perspectives on Infectious Diseases. 2016;2016:5210963.

43 Romanelli F, Empey K, Pomeroy C. Macrocytosis as an indicator of medication (zidovudine) adherence in patients with HIV infection. AIDS Patient Care STDs. 2002;16(9):405–11.

44 Wongdimen Y, Mulyue D, Ferede G. Prevalence and associated factors of thrombocytopenia among HAART-naive HIV-positive patients at Gondar University Hospital, northwest Ethiopia. BMC Res Notes. 2014;7:5.

45 Taremwa IM, Muyindike WR, Muwanguzi E, Boum Y, 2nd Natukunda B. Prevalence of HIV-related thrombocytopenia among clients at Mbarara Regional Referral Hospital, Mbarara, southwestern Uganda. J Blood Med. 2015;5:109–13.

46 Nka AD, Sosso SM, Fokam J, et al. Thrombocytopenia according to antiretroviral drug combinations, viremia and CD4 lymphocytes among HIV-infected patients in Cameroon: a snapshot from the City of Yaounde. BMC Res Notes. 2019;12(1):632.

47 Shen Y, Wang J, Wang Z, et al. A cross-sectional study of leukopenia and thrombocytopenia among Chinese adults with newly diagnosed HIV/AIDS. Bioscience Trends. 2015;9(2):91–6.

48 Nascimento FG, Tanaka KY. Thrombocytopenia in HIV-infected Patients. Indian J Hematol Blood Transfus. 2012;28(2):109–11.

49 Kyeyune R, Seathoff E, Ezemeama AE, Loscher T, Fowzi W, Guwatudde D. Prevalence and correlates of cytopenias in HIV-infected adults initiating highly active antiretroviral therapy in Uganda. BMC Infect Dis. 2014;14:496.

50 Passos AM, Treitinger A, Spada C. An overview of the mechanisms of HIV-related thrombocytopenia. Acta Haematol. 2010;124(1):3–8.

51 Assinger A. Platelets and infection - an emerging role of platelets in viral infection. Front Immunol. 2014;5:649.

52 Gibellini D, Clo A, Morini S, Miserocchi A, Ponti C, Re MC. Effects of human immunodeficiency virus on the erythrocyte and megakaryocyte lineages. World J Virol. 2013;2(2):91–101.

53 Scaramagam A. HIV-related thrombocytopenia. Blood Rev. 2002;16(1):73–6.

54 Ciernik IF, Cone RW, Fehr J, Weber R. Impaired liver function and retroviral activity are risk factors contributing to HIV-associated thrombocytopenia. Swiss HIV Cohort Study AIDS 1999;13(14):1913–20.